The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Outcomes of non-intensive chemotherapy differ for IDH1 and IDH2-mutated AML
Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses real-world data on outcomes for patients with acute myeloid leukemia (AML) with IDH1 or IDH2 mutations treated with intensive or non-intensive chemotherapy. The analysis found that non-intensive treatment was not associated with favorable outcomes for IDH1-mutated patients, whereas those with IDH2 mutations did have favorable outcomes. This underscores that IDH1 and IDH2 mutations behave differently and should not be categorized together. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting fees and/or honoraria: AbbVie, Daiichi Sankyo, Foghorn, Gilead, Novartis, Sellas, Servier, Shattuck Labs, Sumitomo Dainippon, Syndax; Research funding: AbbVie, Arog, Jazz, Gilead, Loxo, Merck, Newave, Novartis, Sellas, Shattuck Labs, Stemline, Sumitomo Dainippon, Takeda, Zentalis.
